The Market Reports

Synopsis

The global market for POC HbA1C Testing was estimated to be worth US$ 550 million in 2024 and is forecast to a readjusted size of US$ 984 million by 2031 with a CAGR of 8.8% during the forecast period 2025-2031.

HbA1c levels, which reflect the average plasma glucose concentration over the preceding three months, play a pivotal role in the diagnosis, assessment, and monitoring of diabetes. HbA1c is your average blood glucose (sugar) levels for the last two to three months. The immediate feedback of HbA1c levels is highly effective for controlling plasma glucose levels and point-of-care (POC) instruments, characterized as fast, portable, and easy-to-use, have been shown to be suitable for providing rapid feedback of HbA1c levels. In this report, we mainly study the devices for POC HbA1C Testing without services.

Market Drivers:

The growing prevalence of diabetes worldwide is a key driver for the POC HbA1c testing market. As the number of diabetic and prediabetic patients continues to rise, there is an increasing need for quick and efficient monitoring solutions to manage blood sugar levels effectively. POC HbA1c testing provides immediate results, allowing for real-time clinical decision-making and reducing patient dependence on centralized laboratories. Additionally, advancements in technology have led to the development of highly accurate, portable, and user-friendly devices, expanding their adoption in hospitals, clinics, and even home settings.

Government initiatives promoting early diabetes detection and personalized treatment plans further boost market growth.

Market Challenges:

Despite its advantages, POC HbA1c testing faces several challenges, including high costs and reimbursement limitations in some healthcare systems, which may hinder widespread adoption. Additionally, variations in accuracy and standardization among different POC devices pose concerns regarding result reliability, especially when compared to laboratory-based testing.

Regulatory approvals and compliance with stringent quality standards also create barriers for manufacturers entering new markets. Furthermore, lack of awareness and limited access to POC testing in certain developing regions restricts its potential reach, requiring further investments in education and healthcare infrastructure.

This report aims to provide a comprehensive presentation of the global market for POC HbA1C Testing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of POC HbA1C Testing by region & country, by Type, and by Application.

The POC HbA1C Testing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding POC HbA1C Testing.

Market Segmentation

By Company

• Abbott
• Siemens Healthineers
• Roche
• Bio-Rad
• GREEN CROSS MEDIS
• Trinity Biotech
• HUMAN Diagnostics
• Sinocare (PTS Diagnostics)
• Erba Diagnostics
• EKF Diagnostics
• OSANG Healthcare
• SD Biosensor
• Aidian
• Boditech Med
• i-SENS

Segment by Type

• Immunoassay
• Boronate Affinity
• Others

Segment by Application

• Hospital and Clinics
• Diagnostic Laboratories
• Others

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.